NCI Trials for Nov. 2020

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Cancer Institute approved the following clinical research studies last month.

For further information, contact the principal investigator listed.


Phase I – PED-CITN-01

3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent and Young Adult (CAYA) Patients with Relapsed/Refractory Hypermutant Cancers

Cancer Immunotherapy Trials Network

Morgenstern, Daniel Alexander

(416) 813-7654


Phase II – A021804

A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

Alliance for Clinical Trials in Oncology

Del Rivero, Jaydira

(240) 805-2888


Phase II – AMC-107

A Phase 2 Trial of Ixazomib for Kaposi Sarcoma

AIDS Malignancy Consortium

Mitsuyasu, Ronald T.

(310) 825-6689


Phase II – EA8184

A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers

ECOG-ACRIN Cancer Research Group

Kumar, Nagi B.

(813) 745-6885


Phase III – EA9181

A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

ECOG-ACRIN Cancer Research Group

Ofran, Yishai

+972-4-7772541


Phase III – EAA181

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

ECOG-ACRIN Cancer Research Group

Kumar, Shaji K.

(507) 284-2017


Phase III – NRG-BN009

Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brain Metastasis Velocity >/= 4 Brain Metastases/Year

NRG Oncology

Gondi, Vinai

(630) 821-6430


Phase Other – A231901CD

Improving Patient-Centered Communication in Breast Cancer: A RCT of a Shared Decision Engagement System (SHADES)

Alliance for Clinical Trials in Oncology

Hawley, Sarah

(734) 936-8816

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login